1,197
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

ORCID Icon, , , , , , , , , & show all
Pages 641-656 | Received 22 Nov 2016, Accepted 19 Apr 2017, Published online: 15 May 2017

Figures & data

Figure 1. Study design

OPV and measles vaccines were given as part of the national immunization program and were not considered as study vaccines; W: week; M: month; OPV: oral polio vaccine; HRV: human rotavirus vaccine; DTPw-HBV/Hib: diphtheriatetanus-whole cell pertussis-hepatitis B vaccine combined with lyophilized Haemophilus influenzae type b tetanus conjugate vaccine; PHiD-CV: 10-valent pneumococcal non-typeable H. Influenzae protein D conjugate vaccine; oral vaccination; intramuscular vaccination; blood sample. Note: blood samples taken at visits 8 and 9 were used for serological assessment of DTPw-HBV/Hib pre- and post-booster and of measles before and after administration of the second vaccine dose.
Figure 1. Study design

Table 1. Demographic characteristics (total vaccinated cohort)

Figure 2. Participant Flow Diagram

TVC: total vaccinated cohort; ATP: according-to-protocol; N: number of children per group; n: number of children with the specified characteristic; AE: adverse event; SAE: serious adverse event.
Figure 2. Participant Flow Diagram

Table 2. Immunogenicity assessed by GSK 22F ELISA for antipneumococcal antibodies and anti-protein D ELISA (ATP cohort for immunogenicity)

Table 3. Functional immune response assessed by opsonophagocytic activity assay (ATP cohort for immunogenicity)

Figure 3. Kinetics of anti-pneumococcal antibody GMCs (ATP cohort for immunogenicity)

GMC: geometric mean concentration; ATP: according-to-protocol; W: weeks; M: months; 6W: pre-primary vaccination; 18W: 1 month post-primary vaccination; 9–10M: 6 months post-primary vaccination (pre-booster in groups 2+1 and 3+1); 10–11M: 7 months post-primary vaccination (1 month post-booster in groups 2+1 and 3+1); 24–27M: 21 months post-primary vaccination (15 months post-booster in groups 2+1 and 3+1). Note: Error bars indicate 95% confidence intervals. Data for the groups are slightly shifted for better visualization.
Figure 3. Kinetics of anti-pneumococcal antibody GMCs (ATP cohort for immunogenicity)

Figure 4. Kinetics of anti-pneumococcal OPA GMTs (ATP cohort for immunogenicity)

OPA: opsonophagocytic activity; GMT: geometric mean titer; ATP: according-to-protocol; W: weeks; M: months; 18W: 1 month post-primary vaccination; 9–10M: 6 months post-primary vaccination (pre-booster in groups 2+1 and 3+1); 10–11M: 7 months post-primary vaccination (1 month post-booster in groups 2+1 and 3+1); 24–27M: 21 months post-primary vaccination (15 months post-booster in groups 2+1 and 3+1). Note: Error bars indicate 95% confidence intervals. Data for the groups are slightly shifted for better visualization.
Figure 4. Kinetics of anti-pneumococcal OPA GMTs (ATP cohort for immunogenicity)

Figure 5. Solicited local and general symptoms (overall per dose; total vaccinated cohort)

N: number of doses (primary/booster). Vomiting and diarrhea were solicited due to co-administration of human rotavirus vaccine and were thus only solicited after visit 2 and visit 3 (i.e. interpretation of the overall/dose results has to be done with caution considering N being the sum of the 3 primary doses). The other general symptoms were solicited at visits 1, 2, and 3, even for the 2+1 group who did not receive PHiD-CV but DTPw-HBV/Hib, human rotavirus, and oral polio vaccines at visit 2. Note: Error bars indicate exact 95% confidence intervals.
Figure 5. Solicited local and general symptoms (overall per dose; total vaccinated cohort)